NCT04919850 is a NA clinical trial of Saccharomyces boulardii and SOD in Obesity, sponsored by Azienda di Servizi alla Persona di Pavia.

Who is sponsoring NCT04919850?

NCT04919850 is sponsored by Azienda di Servizi alla Persona di Pavia.

What drugs are being tested in NCT04919850?

Interventions in NCT04919850: Saccharomyces boulardii and SOD, Placebo.

What condition does NCT04919850 study?

NCT04919850 studies Obesity, Superoxide Dismutase.

Is NCT04919850 still recruiting?

NCT04919850 is currently completed. Last updated 9 June 2021.

Last reviewed 2021-06-09 · How we verify

NCT04919850

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of 60-days Saccharomyces Boulardii and Superoxide Dismutase Supplementation in Obese Adults

Completed NA Last updated 9 June 2021

What this trial tests

NA trial testing Saccharomyces boulardii and SOD in Obesity in 25 participants. Completed in 20 June 2020.

Timeline

15 January 2018

Primary endpoint
28 January 2018

20 June 2020

Quick facts

Lead sponsor	Azienda di Servizi alla Persona di Pavia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	25
Start date	15 January 2018
Primary completion	28 January 2018
Estimated completion	20 June 2020
Sites	1 location across Italy

Drugs / interventions tested

Saccharomyces boulardii and SOD
Placebo

Conditions studied

Obesity — all drugs for Obesity →
Superoxide Dismutase — all drugs for Superoxide Dismutase →

Sponsor

Azienda di Servizi alla Persona di Pavia — full company profile →

Who can join

Adults 30 to 65, any sex, with Obesity or Superoxide Dismutase. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In animals it has been demonstrated that Saccharomyces boulardii decrease low-grade inflammation and fat mass; also Superoxide Dismutase (SOD) decrease low-grade inflammation. Therefore, the aim of this double-blind, placebo-controlled clinical trial was to assess the effect of a 60-days S. boulardii and SOD supplementation on circulating markers of inflammation, body composition, hunger sensation, pro/antioxidant ratio, hormonal, lipid profile, glucose, insulin and HOMA-IR, in obese adults (BMI 30-35 kg/m2).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of 60-Day <i>Saccharomyces boulardii</i> and Superoxide Dismutase Supplementation on Body Composition, Hunger Sensation, Pro/Antioxidant Ratio, Inflammation and Hormonal Lipo-Metabolic Biomarkers in Obese Adults: A Double-Blind, Placebo-Controlled Trial.
Rondanelli M, Miraglia N, Putignano P, Castagliuolo I, et al · · 2021 · cited 15× · PMID 34444671 · DOI 10.3390/nu13082512

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Azienda di Servizi alla Persona di Pavia trials

Trials by the same sponsor.

NCT07377409 — Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Ne · NA · not yet recruiting
NCT06954038 — Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood · NA · not yet recruiting
NCT06955234 — Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose · NA · not yet recruiting
NCT06942897 — Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cor · NA · not yet recruiting
NCT05730985 — From the Gut to the Strut: Reducing Inflammation for Healthy Muscles · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04919850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda di Servizi alla Persona di Pavia
Last refreshed: 9 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04919850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing